Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Delta Hotels Ottawa City Centre

Oct 18, 2022 1:00 PM - Oct 19, 2022 9:10 PM

101 Lyon Street North, Ottawa, ON K1R 5T9, Canada

Canada Annual Meeting

Session 1: Whatever Happened to the Regulatory Review of Drugs and Devices (R2D2) – 2017-2021?

Session Chair(s)

Judith  Mergl, MSc

Judith Mergl, MSc

Director, Regulatory Affairs and Operational Services

AbbVie Corporation, Canada

Yatika  Kohli, PhD, MBA

Yatika Kohli, PhD, MBA

Chief Regulatory and Strategy Officer

NoNO Inc, Canada

In 2017, Health Canada undertook an initiative, commonly referred to as the ‘Regulatory Review of Drugs and Devices’, or ‘R2D2’, to improve the efficiency of Canada’s regulatory system and to provide more timely access to therapeutic products that are aligned with healthcare system needs. In this session, we will provide an overview looking back at the original objectives of R2D2 and the outputs and successes that have been achieved to date of the projects under this initiative. This session will also focus on how the R2D2 has transformed since its inception and how it has helped influence Health Canada’s current regulatory modernization plans.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe what R2D2 was intended to achieve
  • Identify the R2D2 initiatives and their status and the progress achieved
  • Describe how these initiatives have led to Health Canada’s Regulatory Modernization Framework


Celia  Lourenco, PhD

The Evolution of Regulatory Review of Drugs and Devices (R2D2): Celia Lourenco, PhD

Director General, Biologic and Radiopharmaceutical Drugs Directorate, HPFB

Health Canada, Canada

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.